linjc16/ctgov huggingface dataset:
Dietary Intake and Nutrient Status of Children With ADHD

Study Overview
=================
Brief Summary
-----------------
Assess the dietary intake of children aged 6-12 years by means of a 24-hour recall and 3-day food record and asses the nutrient status of Vitamin B6, serum ferritin, serum zinc and serum copper of the same children by means of standard laboratory assessments.

Detailed Description
-----------------
To document the use of vitamin and vitamin-mineral supplements To determine the percent consumption of low nutrient density (LND) foods To compare the dietary intake of ADHD children with the established standards of the Dietary Reference Intakes (DRIs) To compare the dietary intake of children with ADHD to the dietary recommendations of Canada's Food Guide for Healthy Eating To determine whether dietary intake is moderated by drug treatment To assess the pyridoxal-5'-phosphate (PLP), serum ferritin, serum zinc, and serum copper status of ADHD by standard laboratory blood test to measure height and weight in ADHD children

Official Title
-----------------
Dietary Intake and Nutrient Status of Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

Conditions
-----------------
Attention Deficit Hyperactivity Disorder

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Primary diagnosis of ADHD Age 6-12 years inclusive Exclusion Criteria: No use of medication that affects dietary intake (eg. Risperdal)

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
observational, dietary intake, nutrient status, serum assessors, Attention-Deficit/Hyperactivity Disorder (ADHD)
Prophylactic Antibiotics for Manual Removal of Retained Placenta in Vaginal Birth: a Randomized Controlled Trial

Study Overview
=================
Brief Summary
-----------------
Background: There is scarce evidence regarding the necessity of antibiotic prophylaxis in manual revision of the uterus after labor in cases of residual placenta. Methods: a randomized control trial in which parturients for which the placenta was not separated or there is a suspected residual placenta will be divided randomly to two groups: (1) Revision of uterus or Manual lysis without antibiotic prophylaxis; (2) Revision of uterus or Manual lysis with antibiotic prophylaxis as following: 24 hours coverage with Ampicillin 2 grams*4, Gentamycin 240 mg*1, Clindamycin 600 mg*3. In cases of allergy to Penicillin the antibiotic regimen will be: Gentamycin 240 mg*1, Clindamycin 600 mg*3. Outcomes: Puerperal fever, endometritis, length of hospitalization after labor, recurrent hospitalization in the first 2 weeks after discharge.

Official Title
-----------------
Prophylactic Antibiotics for Manual Removal of Retained Placenta in Vaginal Birth

Conditions
-----------------
Endometritis

Intervention / Treatment
-----------------
* Drug: Antibiotic prophylaxis
* Drug: Ampicillin
* Drug: Gentamycin
* Drug: Clindamycin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: suspected retained placenta Exclusion Criteria: Intrapartum fever

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Antibiotic prophylaxis<br>antibiotic prophylaxis as following: 24 hours coverage with Ampicillin 2 grams*4, Gentamycin 240 mg*1, Clindamycin 600 mg*3 | Drug: Antibiotic prophylaxis<br>* antibiotic prophylaxis as following: 24 hours coverage with Ampicillin 2 grams*4, Gentamycin 240 mg*1, Clindamycin 600 mg*3<br>Drug: Ampicillin<br> <br> Drug: Gentamycin<br> <br> Drug: Clindamycin<br> <br> |
| No Intervention: No treatment<br>No antibiotics | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Endometritis rate |  | 3 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Puerperal fever |  | 3 years |
To Pace or Not to Pace in Sinus Node Disease

Study Overview
=================
Brief Summary
-----------------
Optimal pacing strategy for patients with SND is still unknown, although several publications in the past years demonstrated a deleterious effect of ventricular pacing. However, pacing has always been apical in these trials, and to which extent this absence of pacing is beneficial for patients with very long PR intervals is still to be found. The aim of this study is to compare ventricular septal pacing to no pacing in patients with SND.

Official Title
-----------------
Comparison of Ventricular Septal Pacing With Optimized Atrioventricular (AV) Delay to no Pacing in Sinus Node Disease (SND) Patients.

Conditions
-----------------
Sinus Node Disease

Intervention / Treatment
-----------------
* Device: Septal ventricular pacing
* Device: VIP


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with sinus node disease Exclusion Criteria: Complete or high degree AV block Permanent atrial fibrillation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: No pacing<br>Ventricular intrinsic conduction enhanced | Device: VIP<br>* Ventricular pacing must be less than 10%.<br>|
| Experimental: Pacing<br>Septal ventricular pacing with optimized AV delay | Device: Septal ventricular pacing<br>* Ventricular pacing must be at least 90%, from the septum and with optimized AV delay<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Left Ventricular Endsystolic Diameter (LVED) |  | 18 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| AF incidence |  | 18 months | 
| Hospitalizations |  | 18 months |
Prospective Investigation of Cardiovascular Risk Factors in Tumor Patients

Study Overview
=================
Brief Summary
-----------------
In this study, prospective cohort study was used to collect the general information of patients' sex, age, previous history, family history, electrocardiogram, echocardiography, cardiac biomarkers TnT, BNP, biochemical examination, and clinical treatment of the patients who diagnosed cancer by pathology in National Cancer Center/ Cancer Hospital , Chinese Academy of Medical Sciences and Peking Union Medical College from January 2018 to December 2020. This study intends to evaluate and screen the cardiovascular risk of tumor patients during antitumor therapy and to establish a model of cardiovascular risk assessment for tumor patients, providing clinical evidence for the prevention of cardiovascular disease risk associated with cancer patients.

Official Title
-----------------
Prospective Investigation of Cardiovascular Risk Factors in Tumor Patients

Conditions
-----------------
Cardioncology

Intervention / Treatment
-----------------
* Other: Record general information


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of malignant tumor by pathology or cytology Age 18-80, KPS > 70 Epidemiological information, clinical diagnosis and treatment and key information of medication are not missing. The liver and kidney function were in the normal range. All selected patients signed informed consent. Exclusion Criteria: patients diagnosed with congenital heart disease, cardiomyopathy, heart failure, arrhythmia, myocardial ischemia and myocardial infarction within 6 months before enrollment. Severe impairment of liver and kidney function. Left ventricular ejection fraction < 50% by echocardiographic examination. Diagnosis of more than one kind of tumor at the same time. History of surgery and trauma within 3 months before enrollment. Poor compliance

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Observation<br>Record general information of patients' sex, age, previous history, family history, electrocardiogram, echocardiography, cardiac biomarkers TnT, BNP, biochemical examination, and clinical treatment and so on | Other: Record general information<br>* Record general information of patients' sex, age, previous history, family history, electrocardiogram, echocardiography, cardiac biomarkers TnT, BNP, biochemical examination, and clinical treatment of the patients<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse events (AEs) related to Cardio-oncology | Adverse events (AEs) and laboratory tests graded according to the NCI CTCAE (version 4.0) recorded by ECGs,UCGs and myocardial enzyme | January 2018 to December 2020. |
Observational Study on Plasma Glutamine Levels Before and After Cardiac Surgery

Study Overview
=================
Brief Summary
-----------------
Earlier studies showed that a low glutamine level at acute admission on the ICU is associated with a poor outcome [3,4]. Recently, we found that a low plasma glutamine is correlated with severity of illness and presence of an infection after non-elective ICU admission [5, submitted].

Detailed Description
-----------------
It is known that major surgery induces a stress response characterised by hormonal release and inflammatory processes [6,7]. This surgical stress response resembles the catabolic stress which is found in other forms of critical illness. We did not measure plasma glutamine before surgery so it is unknown whether the plasma glutamine level was already low before surgery in these patients or that the lowering of plasma glutamine level is a consequence of surgery. Most of the patients in the elective surgery group in our study underwent cardiac surgery with use of cardiopulmonary bypass; it is known that extracorporeal circulation induces an inflammatory response but there are no clinical data on the effects on plasma glutamine or on post-operative course in relation to plasma glutamine levels [8,9].

Official Title
-----------------
Observational Study on Plasma Glutamine Levels Before and After Cardiac Surgery

Conditions
-----------------
Glutamin Level

Intervention / Treatment
-----------------
* Procedure: no intervention, blood is sampled for routine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients undergoing elective cardiac surgery Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| elective cardiac surgery patients<br>consecutive patients who undergo elective cardio-thoracic surgery during a 6 to 8 week period | Procedure: no intervention, blood is sampled for routine<br>* no intervention, blood sampled for standard evaluation will be used for determination of plasma glutamin<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| plasma glutamine |  | intraoperative |
the Impact of EECP on Intraocular Pressure

Study Overview
=================
Brief Summary
-----------------
EECP therapy may affect the intraocular pressure while improving the ischemia systemic organ blood perfusion the same time. The present study investigated the impact of Enhanced Extracorporeal Counterpulsation treatment on the intraocular pressure.

Detailed Description
-----------------
Select 40 cases of patients (80eyes) who had counter pulsation treatment at Enhanced External Counter Pulsation (EECP) Specialist in First Affiliated Hospital of Sun Yat-sen University during Apr 2012 - Mar 2013. Separated the patients into 2 groups according to having glaucoma history or not.The cases whose eyes have erythralgia and who have received corneal surgery or intraocular surgery in recent one month are excluded.

Official Title
-----------------
Study of the Impact of Enhanced Extracorporeal Counterpulsation Treatment on Intraocular Pressure

Conditions
-----------------
Intraocular Pressure

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: counter Enhanced External Counter Pulsation treatment Exclusion Criteria: whose eyes have erythralgia who have received corneal surgery or intraocular surgery in recent one month Hemorrhagic disease Atrial fibrillation Aortic regurgitation thrombophlebitis or infection lesions severe hypertensive

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Intraocular pressure, EECP, no glaucoma<br>To examine no glaucoma patients' intraocular pressure before and after the treatment of Enhanced Extracorporeal Counterpulsation. EECP one hour per day, 5 hours a week for a total of 35 hours lasting 7 weeks | |
| intraocular pressure, EECP, glaucoma<br>To examine glaucoma patients' intraocular pressure before and after the treatment of Enhanced Extracorporeal Counterpulsation. EECP one hour per day, 5 hours a week for a total of 35 hours lasting 7 weeks. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| intraocular pressure |  | 7 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ophthalmic and retina artery blood flow rate |  | 7 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Enhanced Extracorporeal Counterpulsation, intraocular pressure, Pen type tonometer
Study Comparing Pitavastatin and Atorvastatin in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare the efficacy and safety of pitavastatin with that of atorvastatin in patients with type II diabetes mellitus (type II DM) and combined dyslipidemia.

Official Title
-----------------
Study of Pitavastatin Vs. Atorvastatin (Following Up-Titration) in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia

Conditions
-----------------
Type II Diabetes Mellitus, Dyslipidemia

Intervention / Treatment
-----------------
* Drug: Pitavastatin
* Drug: Atorvastatin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males and females (ages 18-75 years) Type II DM treated with oral anti-diabetic medication (sulfonylurea, metformin, glitazones, or combination therapy) Must have been following a restrictive diet Diagnosis of combined dyslipidemia Exclusion Criteria: Homozygous familial hypercholesterolemia Conditions which may cause secondary dyslipidemia Uncontrolled diabetes mellitus Abnormal pancreatic, liver, or renal function Abnormal serum creatine kinase (CK) above the pre-specified level Significant heart disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Pitavastatin 4 mg QD<br>Pitavastatin 4 mg once daily | Drug: Pitavastatin<br>* Pitavastatin 4 mg QD<br>|
| Active Comparator: Atorvastatin 20 mg QD<br>Atorvastatin 20 mg once daily | Drug: Atorvastatin<br>* Atorvastatin 20 mg<br>* Other names: Lipitor;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percent Change From Baseline Low Density Lipoprotein Cholesterol (LDL-C) | Percent change from baseline to Week 12 low density lipoprotein cholesterol (LDL-C) | 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Patients Attaining National Cholesterol Education Program (NCEP) LDL-C Target | Number of patients attaining National Cholesterol Education Program (NCEP)LDL-C target (LDL-C less than 160 mg/dL) at 12 weeks | 12 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Kowa, Type II Diabetes Mellitus, Combined Dyslipidemia, pitavastatin, NK-104, Atorvastatin
Prevalence of DVT or PE in Patients Infected With COVID-19 Admitted to Hospital

Study Overview
=================
Brief Summary
-----------------
The main objectives are: To establish the prevalence of deep venous thrombosis through ultrasonography in Patients infected with COVID-19 admitted to hospital. To identify patients with higher risk of deep venous thrombosis.

Official Title
-----------------
Prevalence of DVT or PE in Patients Infected With COVID-19 Admitted to Hospital (SCREENING Study)

Conditions
-----------------
COVID-19

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients infected with COVID-19. Admission to hospital. Exclusion Criteria: Patients treated with ECMO (Extracorporeal membrane oxygenation).
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| VTE events and complications | Study endpoints are clinically recognized (and objectively confirmed) recurrences of VTE, major and minor bleeding complications, and death. | 30 days |
The Effect of Contrast Agent on Endothelial Function in Healthy Men

Study Overview
=================
Brief Summary
-----------------
Contrast medium is essential for diagnosis of many diseases. However, recent studies showed that contrast agents can induce renal injury and is associated with poor long-term clinical outcome, especially in diabetes. To date, no data are available on the relationship between contrast medium and endothelial function. Endothelial dysfunction is known to precede atherosclerosis and is considered a risk marker for future development of cardiovascular disease. Therefore, we hypothesized that contrast agents may induce endothelial dysfunction in healthy men. In addition, we hypothesized that contrast induced endothelial dysfunction via free radicals. Thus, we also test alpha-lipoic acid whether or not protect endothelial dysfunction induced by contrast agents.

Official Title
-----------------
The Effect of Contrast Agent on Endothelial Function in Healthy Men

Conditions
-----------------
Contrast Agent, Endothelial Function, Cytokines, Apoptosis of Endothelial Progenitor Cell, Free Radical, Alpha-lipoic Acid

Intervention / Treatment
-----------------
* Other: Contrast agent


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy men 20 yr < = age < = 30 yr 20 < = body mass index < = 25 Exclusion Criteria: age < 20 yr or > 30 yr dysfunction for liver, renal, and heart. other diseases such as diabetes, hypertension, thyroid disease

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 30 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: contrast group (Ioversol)<br>Each individual will be given 80 ml Ioversol via intravenous injection within 5 minutes | Other: Contrast agent<br> <br> |
| Placebo Comparator: Placebo group<br> | |
| Other: alpha-lipoic acid group<br>Alpha-lipoic acid 600 mg in 0.9% sodium chloride 250 ml was administrated 1 hour before contrast agents via venous. and only 0.9% sodium chloride 250 ml was administrated for other 2 groups. | Other: Contrast agent<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The endothelial dysfunction and the protective role of alpha-lipoic acid |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The apoptosis of endothelial progenitor cell |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Contrast agent, endothelium, Free radical, Alpha lipoic acid